MA21.03 The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer
Matthew P. Smeltzer(University of Tennessee Health Science Center), Fred R. Hirsch(Tisch Hospital), Pieter E. Postmus(Leiden University Medical Center), Charles A. Powell(Icahn School of Medicine at Mount Sinai), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), E. Kim(Levine Cancer Institute), Ross A. Soo(National University Cancer Institute, Singapore), Masahiro Tsuboi(National Cancer Center Hospital East), Kristen E. Howell(Texas A&M University), Sylvie Lantuéjoul(Centre Léon Bérard), Murry W. Wynes(International Association for the Study of Lung Cancer), K. Richeimer(International Association for the Study of Lung Cancer), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Enriqueta Felip(Institut Català d'Ornitologia), Mercedes Dalurzo(Hospital Italiano de Buenos Aires), Clarissa Mathias(Apple (Israel)), S. Ramalingam(Emory University), K. Wood(International Association for the Study of Lung Cancer), Keith M. Kerr(University of Aberdeen), Meghan M. Taylor(University of Memphis)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k